The role of the 11β-hydroxysteroid dehydrogenase type 2 in human hypertension

Journal of Hypertension

Volumn 18, Issue 3, 2000, Pages 241-248

  Ferrari, Paolo ^a   Lovati, Emanuela ^b   Frey, Felix J ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

11 hydroxysteroid dehydrogenase type 2; Apparent mineralocorticoid excess; Genetics; Hypertension; Mineralocorticoid receptor; Renal sodium retention

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; CARBENOXOLONE; CORTISONE; GLYCYRRHETINIC ACID; GOSSYPOL; HYDROCORTISONE; HYDROXYSTEROID; MICROSATELLITE DNA; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; POTASSIUM; RENIN; SODIUM; SODIUM CHLORIDE; GLUCOCORTICOID; HYDROXYSTEROID DEHYDROGENASE;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GENE MUTATION; GENETIC POLYMORPHISM; GLYCYRRHIZA; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOKALEMIA; PHENOTYPE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SODIUM BLOOD LEVEL; SODIUM RETENTION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; GLUCOCORTICOIDS; HUMANS; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; MINERALOCORTICOIDS; RECEPTORS, MINERALOCORTICOID;

EID: 0033622032     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018030-00001     Document Type: Review

References (75)

1. 1 Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583-585.
2. 2 Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutano WS, et al. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 11:986-989
3. 3 Funder JW, Pearce PT, Myles K, Roy LP. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action. FASEB J 1990; 4:3234-3238.
4. 4 Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ. Tumor necrosis factor α and interleucin 1β enhance the cortisone/cortisol shuttle. J Exp Med 1997; 186:189-198.
5. 5 Agarwal AK, Monder C, Eckstein B, White PC. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J Biol Chem 1989; 264:18939-18943.
6. 6 Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991; 266:16653-16658.
7. 7 Walker BR, Campbell JC, Williams BC, Edwards CRW. Tissue-specific distribution of the NAD+ dependent isoform of 11β-hydroxysteroid dehydrogenase. Endocrinology 1992; 131:970-972.
8. 8 Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105:R11-R17.
9. 9 Agarwal AK, Mune T, Monder C, White PC. NAD+-dependent isoform of 11β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J Biol Chem 1994; 269:25959-25962.
10. 10 Li KXS, Obeyesekere VR, Krozowski ZS, Ferrari P. Oxoreductase and dehydrogenase activities of the cloned 11β-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology 1997; 138:2948-2952.
11. 11 Krozowski ZS, Maguire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 1995; 80:2203-2209.
12. 12 Escher G, Vogt B, Beck T, Guntern D, Frey BM, Frey FJ. Reduced 11β-hydroxysteroid dehydrogenase activity in the remaining kidney following nephrectomy. Endocrinology 1998; 139:1533-1539.
13. 13 Whorwood C, Sheppard MC, Stewart PM. Liquorice inhibits 11β-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993; 132:2287-2292.
14. 14 Teelucksingh S, Mackie ADR, Burt D, McIntyre MA, Brett L, Edwards CRW. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid: Lancet 1990; 335:1060-1063.
15. 15 Palmer LG, Frindt G. Regulation of apical membrane Na and K channels in rat renal collecting tubules by aldosterone. Semin Nephrol 1992; 12:37-43.
16. 16 Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992; 19:221-227.
17. 17 Duchatelle P, Ohara A, Ling BN, Kemendy AE, Kokko KE, Matsumoto PS, et al. Regulation of renal epithelial sodium channels. Mol Cell Biochem 1992; 114:27-34.
18. 18 Wehling M. Nongenomic aldosterone effects: the cell membrane as a specific target of mineralocorticoid action. Steroids 1995; 60:153-156.
19. 19 Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237:268-275.
20. 20 Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94:14924-14929.
21. 21 Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, et al. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999; 103:683-689.
22. 22 Werder EA, Zachmann M, Vollmin JA, Veyrat R, Prader A. Unusual steroid excretion in a child with low renin hypertension. Res Steroids 1974; 6:385-389.
23. 23 New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977; 44:924-933.
24. 24 Ulick S, Levine SL, Gunczler P, Zanconato G, Ramirez LC, Rauh W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49:757-763.
25. 25 Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nature Genetics 1995; 10:394-399.
26. m 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80:3381-3383.
27. 27 Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80:2263-2266.
28. 28 Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CHL, Hanauske-Abel HM, et al. Several mutations in the HSD11B2 gene in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80;3145-3150.
29. 29 Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS. Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 1996; 119:21-24.
30. 30 Ferrari P, Obeyesekere VR, Li K, Andrews RK, Krozowski ZS. The 11β-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation. Steroids 1996; 61:197-200.
31. 31 Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, et al. Human hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1995; 1:88-91.
32. 32 Kitanaka S, Katsumata N, Tanae A, Hibi I, Takeyama K, Fuse H, et al. A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1997; 82:4054-4058.
33. 33 Li A, Li KXZ, Marui S, Krozowski ZS, Batista MC, Whorwood CB, et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens 1997; 15:1397-1402.
34. 34 Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244-2254.
35. 35 Wilson RC, Dave-Sharma S, Wei J-Q, Obeyesekere VR, Li K, Ferrari P, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci USA 1998; 95:10200-10205.
36. 36 Odermatt A, Arnold P, Repetto H, Dick B, Frey BM, Frey FJ, et al. A mutation in the cofactor binding domain of the renal 11β-hydroxysteroid dehydrogenase type 2 causing mineralocorticoid hypertension [abstract]. J Am Soc Nephrol 1999; 10:352A.
37. 37 Li A, Tedde R, Krozowski ZS, Pala A, Li KXZ, Shackleton CHL, et al. Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. Am J Hum Genet 1998; 63:370-379.
38. 38 Mantero F, Tedde R, Opocher G, Fulgheri P, Arnaldi G, Ulick S. Apparent mineralocorticoid excess type II. Steroids 1994; 59:80-83.
39. 39 Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2:821-824.
40. 40 Beretta-Piccoli C, Davies DL, Boddy K, Brown JJ, Cumming AM, East BW, et al. The relation of arterial pressure with plasma and body electrolytes is similar in Conn's syndrome and essential hypertension. Clin Sci 1982; 63:89-92.
41. 41 Walker BR, Stewart PM, Shackleton C, Padfield PL, Edwards C. Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol 1993; 39:221-227.
42. 42 Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R. Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension 1995; 25:67-70.
43. 43 Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CR. Increased vasoconstrictor sensitivity to glucocorticoid in essential hypertension. Hypertension 1996; 27:190-196.
44. 44 Walker BR, Phillips DIW, Noon JP, Panarelli M, Andrew R, Edwards HV, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998; 31:891-895.
45. 45 Litchfield WR, Hunt SC, Jeunemaitre X, Fisher NDL, Hopkins PN, Williams RR, et al. Increased urinary free cortisol. A potential phenotype of essential hypertension. Hypertension 1998; 31:569-574.
46. 46 Iki K, Miyamori I, Hatakeyama H, Yoneda T, Takeda Y, Takeda R, et al. The activities of 5β-reductase and 11β-hydroxysteroid dehydrogenase in essential hypertension. Steroids 1994; 59:656-660.
47. 47 Santini DL, Lorenzo BJ, Koufis T, Reidenberg MM. Cortisol metabolism in hypertensive patients who do and do not develop hypokalemia from diuretics. Am J Hypertens 1995; 8:516-519.
48. 48 Sullivan JM. Salt sensitivity. Definition, conception, methodology and long-term issues. Hypertension 1991; 17 (Suppl. 1):61-68.
49. 49 Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27:481-490.
50. 50 Sharma AM. Salt sensitivity as a phenotype for genetic studies of human hypertension. Nephrol Dial Transplant 1996; 11:927-929.
51. 51 Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, et al. Molecular basis of human salt-sensitivity: the role of the 11β-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999; 84:3745-3749.
52. 52 Palermo M, Shackleton CHL, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol 1996; 45:605-611.
53. 53 Krozowski ZS, Stewart PM, Obeyesekere VR, Li K, Ferrari P. Mutations in the 11β-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth. Clin Exp Hypertens 1997; 19:519-529.
54. 54 Burton PJ, Waddell BJ. 11β-Hydroxysteroid dehydrogenase in the rat placenta: developmental changes and the effects of altered glucocorticoid exposure. J Endocrinol 1994; 143:505-513.
55. 55 Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Br Med J 1989; 298:564-567.
56. 56 Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996; 39:1299-1305.
57. 57 Edwards C, Benediktsson R, Lindsay RS, Seckl JR. Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet 1993; 1:355-357.
58. 58 Seckl JR, Benediktsson R, Lindsay RS, Brown RW. Placental 11β-hydroxysteroid dehydrogenase and the programming of hypertension. J Steroid Biochem Mol Biol 1995; 55:447-455.
59. 59 McCalla CO, Nacharaju VL, Muneyyirci-Delale O, Glasgow S, Feldman JG. Placental 11β-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies. Steroids 1998; 63:511-515.
60. 60 Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991; 72:1060-1066.
61. 61 Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996; 14:S37-S41.
62. 62 Fanestil DD. Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptors. Biochem Pharmacol 1968; 17:2240-2242.
63. 63 Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 1992; 263:E1125-E1130.
64. 64 Funder JW. Mineralocorticoid receptors in the central nervous system. J Steroid Biochem Mol Biol 1996; 56:179-183.
65. 65 Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339:1787-1788.
66. 66 Watson B, Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of flanking microsatellites with essential hypertension in blacks. Hypertension 1996; 28:478-482.
67. 67 Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ, et al. A new polymorphic restriction site in the human 11β-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998; 83:1814-1817.
68. 68 Brand E, Kato N, Chatelain N, Krozowski ZS, Jeunemaitre X, Corvol P, et al. Structural analysis and evaluation of the 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) gene in human essential hypertension. J Hypertens 1998; 16:1627-1633.
69. 69 Sang GW, Lorenzo NJ, Reidenberg MM. Inhibitory effects of gossypol on corticosteroid 11β-hydroxysteroid dehydrogenase from guinea pig kidney: a possible mechanism for causing hypokalemia. J Steroid Biochem 1991; 39:169-176.
70. 70 Song D, Lorenzo BJ, Reidenberg MM. Inhibition of 11β-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J Lab Clin Med 1992; 120:792-797.
71. 71 Morris DJ, Semafuko WE, Latif SA, Vogel B, Grimes CA, Sheff MF, Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension 1992; 20:356-360.
72. 72 Takeda Y, Miyamori I, Iki K, Inaba S, Furukawa K, Hatakeyama H, et al. Endogenous renal 11β-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 1996; 27:197-201.
73. 73 Lo YH, Sheff MF, Latif SA, Ribeiro C, Silver H, Brem AS, et al. Kidney 11βHSD2 is inhibited by glycyrrhetinic acid-like factors in human urine. Hypertension 1997; 29 (1 Pt 2):500-505.
74. 74 Morris DJ, Lo YH, Litchfield WR, Williams GH. Impact of dietary Na+ on glycyrrhetinic acid-like factors (kidney 11β-(HSD2)-GALFs) in human essential hypertension. Hypertension 1998; 31 (Part 2):469-472.
75. 75 Souness GW, Morris DJ. 11α-and 11β-Hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension 1996; 27 (3 Pt 1):421-425.